Closed Loop Oxygen Control in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Nasal High Flow in the Hospital

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Fisher and Paykel Healthcare
Study ID
NCT07222410
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
22 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Closed loop oxygen control — DEVICE
    Nasal high flow with closed loop oxygen control
  • Manual titration — DEVICE
    Nasal high flow with manual titration

Study Details

The trial aims to evaluate whether the Airvo 3 device in OptiO2 mode can maintain patients' SpO2 levels within the target range better than manual oxygen titration in hospitalized COPD patients with hypoxemia/respiratory distress.

Key Dates

First listed
Oct 29, 2025
Start date
Jan 7, 2026
Status verified
Oct 2025
Primary completion
Nov 30, 2027
Completion
Nov 30, 2027

Study Design

Enrollment
70 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Airvo 3 (with OptiO2) OptiO2 mode on
  • Active Comparator: Airvo 3 (with OptiO2) OptiO2 mode off

Primary Outcome Measure

Percentage of time with SpO2 in target range over period of observation [ Time Frame: 24 hours ]

Central Contacts

Locations (4)

FacilityCityStateZIPSite coordinators
The University of Alabama at BirminghamBirminghamAlabama35294
Raymond C Wade
205-934-2490
Central Iowa Hospital Corp - UnityPoint HealthDes MoinesIowa50309
Matthew Trump
515-205-4013
Icahn School of Medicine at Mount SinaiNew YorkNew York10029
Kathryn Dubowski
212-420-2377
Temple University HospitalPhiladelphiaPennsylvania19140
Gerard Criner
215-707-8113

Find similar trials in Birmingham, AL

By condition

Related Studies